BioCentury | Jun 19, 2020
Product Development

June 18 Quick Takes: Approvals for Ultragenyx, Epizyme, Merck; plus Tecfidera tussle, Tecentriq in TNBC, Sarepta-Selecta, and Gelesis goes to China

A first from Ultragenyx in a rare disease  FDA approved Crysvita burosumab-twza from Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) to treat tumor-induced osteomalacia in patients age two and older. The anti-FGF23 mAb is the first to be...
BC Extra | Apr 15, 2019
Company News

Gelesis' weight loss aid gains U.S. approval

Gelesis said Sunday it received FDA clearance for Plenity (Gelesis100), making the prescription weight loss product available to patients who are ineligible for gastric bypass surgery. Plenity is indicated for use as an aid in...
BC Innovations | Jan 11, 2019
Product R&D

PureTech turns inward

After a 15-year run of spinning out technologies into affiliate companies, PureTech Health plc is stepping away from that model in favor of an internal pipeline to advance its new platforms. Behind the structural shift...
BC Week In Review | Nov 16, 2018
Clinical News

Gelesis submits device application to FDA for hydrogel weight loss product

Gelesis Inc. (Boston, Mass.) said it submitted a medical device marketing application to FDA over the summer for weight loss product Gelesis100 as an adjunct to a hypocaloric diet and moderate physical activity. The company...
BC Week In Review | Sep 29, 2017
Clinical News

Gelesis reports mixed data for hydrogel weight loss product

Gelesis Inc. (Boston, Mass.) said lead candidate Gelesis100 met 1 of 2 co-primary endpoints in the pivotal GLOW weight loss trial. COO David Pass told BioCentury the company plans to submit the product for regulatory...
BC Extra | Sep 25, 2017
Clinical News

Gelesis reports mixed data for hydrogel weight loss product

Gelesis Inc. (Boston, Mass.) said lead candidate Gelesis100 met one of two co-primary endpoints in the pivotal GLOW weight loss trial. COO David Pass told BioCentury the company plans to submit the product for regulatory...
BC Extra | Dec 19, 2015
Financial News

Gelesis raises $31.5M

Gelesis Inc. (Boston, Mass.) raised $31.5 million in a growth financing that came a day after Gelsis withdrew its proposed IPO. New investors including Cormorant Asset Management joined existing investors Invesco Asset Management, PureTech and...
BC Extra | May 14, 2015
Financial News

Obesity play Gelesis postpones IPO

Obesity device developer Gelesis Inc. (Boston, Mass.) postponed its IPO on NASDAQ, which was to be underwritten by Piper Jaffray; Stifel; and Guggenheim. Last month, Gelesis said it hoped to sell 4 million shares at...
BC Week In Review | Jan 26, 2015
Clinical News

Gelesis100: Pivotal trial started

Gelesis began the 6-month, double-blind, placebo-controlled, international, pivotal GLOW trial to evaluate twice-daily oral Gelesis100 in about 168 overweight and obese patients with and without Type II diabetes. The company plans to seek CE Mark...
BC Extra | May 17, 2014
Financial News

Obesity play Gelesis raises $12 million

Gelesis Inc. (Boston, Mass.) raised $12 million from Pritzker/Vlock Family Office and PureTech Ventures as well as other undisclosed investors. Gelesis is developing Gelesis100, an absorbent hydrogel that expands in the stomach and adjusts the...
Items per page:
1 - 10 of 11